论文信息 - Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. - 字舞流文

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

H. Wajant | G. Fey | A. A. van de Loosdrecht | W. Helfrich | M. Chamuleau | J. Stieglmaier | E. Bremer | D. Samplonius | N. Mueller | B. ten Cate | A. Stel